StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Monday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $1.17 on Monday. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81. The company has a 50 day simple moving average of $0.74 and a two-hundred day simple moving average of $1.80.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of EGRX. Creative Planning bought a new position in shares of Eagle Pharmaceuticals in the third quarter worth about $59,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals in the third quarter worth about $453,000. RBF Capital LLC boosted its stake in Eagle Pharmaceuticals by 11.7% in the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the period. Jane Street Group LLC bought a new position in Eagle Pharmaceuticals in the 3rd quarter worth approximately $96,000. Finally, DGS Capital Management LLC boosted its stake in Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the period. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.